Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy of prednisone and tripterygium wilfordii in treated Focal Segmental Glomerulosclerosis (FSGS).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing University School of Medicine
• Treatments: Prednisone

Criteria

Inclusion Criteria:

• Age 18-60 years at onset of signs or symptoms of FSGS

• Urine protein ≥ 3.5 g/24 h

• Estimated glomerular filtration rate (GFR) ≥ 40 ml/min/1.73 m2, serum creatinine<2.5mg/dl

• Biopsy confirmed as idiopathic FSGS (including all subtypes)

• Willingness to follow the clinical trial protocol, including medications, and baseline and follow-up visits and procedures

Exclusion Criteria:

• Secondary FSGS

• Prior therapy with sirolimus, Cyclosporine, MMF, azathioprin, cytoxan, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days

• Active/serious infection

• Malignancy

• Previously diagnosed as diabetes mellitus type 1 or 2, or abnormal carbohydrate tolerance

• Peripheral white blood cells < 3000/ul

• Clinical evidence of cirrhosis or chronic active liver diseases

• History of significant gastrointestinal disorder

• Allergy to study medications, and Inability to consent/assent